Stephen Hoge Sells 318 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 318 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $76.99, for a total transaction of $24,482.82. Following the completion of the transaction, the president now owns 1,443,002 shares of the company’s stock, valued at $111,096,723.98. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Stephen Hoge also recently made the following trade(s):

• On Thursday, August 29th, Stephen Hoge sold 300 shares of Moderna stock. The stock was sold at an average price of $78.03, for a total transaction of $23,409.00.
• On Monday, August 12th, Stephen Hoge sold 254 shares of Moderna stock. The stock was sold at an average price of $84.10, for a total value of $21,361.40.
• On Monday, July 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00.
• On Monday, June 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $138.16, for a total value of $2,072,400.00.

Moderna Stock Down 0.7 %

Shares of NASDAQ:MRNA opened at $72.89 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The business’s 50 day simple moving average is $100.18 and its two-hundred day simple moving average is $112.42. The firm has a market cap of $27.93 billion, a P/E ratio of -4.65 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The company had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period in the prior year, the firm earned ($3.62) earnings per share. Moderna’s revenue for the quarter was down 29.9% on a year-over-year basis. As a group, research analysts forecast that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Thursday, August 1st. HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective for the company in a research report on Wednesday, August 28th. JPMorgan Chase & Co. dropped their target price on shares of Moderna from $96.00 to $88.00 and set a “neutral” rating on the stock in a report on Thursday, August 15th. The Goldman Sachs Group cut their price target on shares of Moderna from $204.00 to $178.00 and set a “buy” rating on the stock in a research report on Friday, August 2nd. Finally, William Blair reissued a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. Ten analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $123.79.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Sanctuary Advisors LLC acquired a new stake in shares of Moderna in the 2nd quarter worth about $3,140,000. Teachers Retirement System of The State of Kentucky increased its holdings in Moderna by 4.3% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 283,909 shares of the company’s stock worth $33,714,000 after purchasing an additional 11,828 shares in the last quarter. Ariadne Wealth Management LP purchased a new stake in shares of Moderna in the second quarter worth approximately $2,372,000. Granite Bay Wealth Management LLC purchased a new stake in shares of Moderna in the second quarter worth approximately $524,000. Finally, Truist Financial Corp lifted its holdings in shares of Moderna by 7.3% in the second quarter. Truist Financial Corp now owns 18,657 shares of the company’s stock valued at $2,216,000 after purchasing an additional 1,275 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.